Yasemin Ozsurekci

Projects 1. Preoperatif barsak temizliği ve/veya perioperatif probiyotik uygulamasının barsak anastomozu üzerine etkileri. HÜBAB (Destek Projesi), Project no: TDS-2015-6415. Subinvestigator. 2. Biomarker Identification via Invivo Microbial Antigen Discovery. Discovery of Secreted Circulating and In Vivo Amplified Bacterial Antigens. Grant award number: HDTRA1-16-1- 0055. Sub-investigator. 3. Phylogeography of Francisella Tularensis Subspecies Holarctica from the Country of Turkey. Department of Homeland Security Science and Technology Directorate award number: NBCH2070001 and Cowden Endowment in Microbiology at Northern Arizona University. Project managers [Yasemin Ozsurekci (Turkey) and David M. Wagner (USA)]. Study period: 2011-2013. 4. Genotyping of Turkish Brucella Isolates Using Multiple-Locus Variable-Number Tandem Repeat Analysis and Whole Genome Sequencing. Department of Homeland Security Science and Technology Directorate award number: NBCH2070001 and Cowden Endowment in Microbiology at Northern Arizona University. Project managers [Yasemin Ozsurekci (Turkey) and David M. Wagner (USA)]. Study period: 2010-2015. 5. A Phase III, observer blind, randomized, non-influenza vaccine comparator-controlled, multi-country and multi-centre study of the efficacy of GSK Biologicals’ quadrivalent, inactivated, split virion, seasonal influenza vaccine candidate, GSK2282512A (FLU Q-QIV), administered intramuscularly in healthy children 3 to 8 years of age. Sub-investigator. GSK Biological’s vaccine clinical study. Study period: 2010-2011. 6. A Phase III, randomised, open, controlled, multicentre, primary vaccination study to evaluate the immunogenicity and persistence of 1 and 2 doses of GlaxoSmithKline Biologicals’ meningococcal conjugate vaccine MenACWY-TT in toddlers (after 1 month and up to 5 years) and to demonstrate noninferiority of co-administration of MenACWY-TT and Pfizer’s 13-valent pneumococcal conjugate vaccine Prevenar 13 TM versus separate administration of the 2 vaccines. Sub-investigator. GSK Biological’s vaccine clinical study. Study period: 2011-2016. 7. A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virüs-Like Particle (VLP) Vaccine, in 16- to 26- year-old Men and 16- to 26- year-old Women (Protocol no: V503-003). Sub-investigator. MSD vaccine clinical study. Study period: 2014-2015. 8. A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of a 2-dose regimen of V503, a Multivalent Human Papillomavirus (HPV) L1 Virüs-Like Particle (VLP) Vaccine, administered in Preadolescents and Adolescents (9- to 14-year-olds) with a comparison to Young Women (16- to 26-year-olds). (Protocol no: V503-010). Subinvestigator. MSD vaccine clinical study. Study period: 2014-2018. 9. Preoperatif barsak temizliği ve/veya perioperatif probiyotik uygulaması sonrası barsak anastomoz hattındaki yara iyileşme sürecinin kollajen yapımı ve anjiogenezis açısından immünohistokimyasal yöntemler kullanılarak değerlendirilmesi. Project manager. HÜBAB (Hızlı Destek Projesi), Project no: THD-2017-11585. Bugget: 25080,04 TL. Study period: July 2017-November 2018. 10. Çocuk Hastalarda Pnömonide Endotelyal Aktivasyon Belirteçleri ve Oksidatif Stresin Yeri. Project manager. TÜBİTAK (3001-Başlangıç Ar-Ge Projeleri Destekleme Programı), Project no: 216S316. Bugget: 56.899,30 TL. Study period: March 2018-March 2019. 11. Çocuklarda akut ve subakut ensefalitlerin etiyolojisinde viral ve otoimmün etkenlerin dağılımı: Prospektif bir çalışma. Sub-investigator. HÜBAB (Hızlı Destek Projesi), Project no: THD-2017-15724. Bütçe: 29430 TL. Study period: October 2017-April 2019. 12. Kırım-Kongo Kanamalı Ateşi’ne (KKKA) Karşı Viral Enfeksiyonu Önleyici ve/veya Viral Genom Hedefli Terapötik Stratejilerin Geliştirilmesi. (Araştırmacı/Uzman). TÜBİTAK (1001). Proje no: 119S440. Bugget: 581500 TL. Study period: 01.12.2019-01.08.2022. 13. Sağlıklı Bebeklerde Güvenlilik, Tolerabilite ve İmmünojenisite Açısından V114’ün ve Prevenar 13’ün Birbirinin Yerine Kullanılabilirliğini Değerlendiren Faz 3, Çok Merkezli, Randomize, Çift Kör Çalışma (PNEU-DIRECTION)/ V114-027 (MSD). (Sub-investigator). 14. COVID-19 Pozitif Çocuklarda Erişkinlere Kıyasla İyi Klinik Seyir Sitokin ve Kemokin Cevaplarıyla Açıklanabilir mi? Project manager. HÜBAB (Hızlı Destek Projesi), Project no: THD-2020-18774. Bütçe: 35958,14 TL. Study period: May 2020-December 2020. 15. Çocukluk Çağı Toplum Kökenli Pnömonilerinde TLR2 ve TLR4 Tanıda ve Prognozda Kullanışlı Biyobelirteçler Olabilir mi. Project manager. HÜBAB (Hızlı Destek Projesi), Project no: THD-2021-19459. Bütçe: 28996,92 TL. Study period: November 2021-July 2022. 16. CPVID-19 İlişkili MISC Sendromu Patofizyolojisi Sitokin ve Kemokin Cevaplarıyla Açıklanabilir mi? Project manager. HÜBAB (Hızlı Destek Projesi), Project no: THD-2021- 19591. Bugget: 33990,0 TL. Study period: September 2021-March 2022.